for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK

Latest Trade

78.78USD

Change

0.00(0.00%)

Volume

6,515,116

Today's Range

78.22

 - 

79.31

52 Week Range

65.25

 - 

92.64

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
78.78
Open
78.57
Volume
6,515,116
3M AVG Volume
229.20
Today's High
79.31
Today's Low
78.22
52 Week High
92.64
52 Week Low
65.25
Shares Out (MIL)
2,524.10
Market Cap (MIL)
198,848.70
Forward P/E
14.87
Dividend (Yield %)
3.10

Next Event

Q2 2020 Merck & Co Inc Earnings Call

Latest Developments

More

FDA Approves First-Line Immunotherapy For Patients With Msi-H/Dmmr Metastatic Colorectal Cancer

FDA Approves Merck's Keytruda For The Treatment Of Recurrent Or Metastatic Cutaneous Squamous Cell Carcinoma

FDA Says Approves Pembrolizumab For Cutaneous Squamous Cell Carcinoma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

KENILWORTH, NJ

07033-1310

United States

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Chairman of the Board, President, Chief Executive Officer

Robert M. Davis

Executive Vice President, Global Services, Chief Financial Officer

Steven C. Mizell

Executive Vice President, Chief Human Resources Officer, Human Resources

Michael T. Nally

Executive Vice President, Chief Marketing Officer

Jennifer L. Zachary

Executive Vice President, General Counsel, Corporate Secretary

Key Stats

2.00 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

40.1K

2018

42.3K

2019

46.8K

2020(E)

47.2K
EPS (USD)

2017

3.980

2018

4.340

2019

5.190

2020(E)

5.299
Price To Earnings (TTM)
19.82
Price To Sales (TTM)
4.14
Price To Book (MRQ)
7.59
Price To Cash Flow (TTM)
14.45
Total Debt To Equity (MRQ)
106.84
LT Debt To Equity (MRQ)
82.57
Return on Investment (TTM)
16.29
Return on Equity (TTM)
12.18

Latest News

Latest News

BRIEF-FDA Approves Merck's Keytruda For The Treatment Of Recurrent Or Metastatic Cutaneous Squamous Cell Carcinoma

* FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) THAT IS NOT CURABLE BY SURGERY OR RADIATION Source text for Eikon: Further company coverage:

BRIEF-Targovax Announces Collaborative Agreement With Merck & Co

* TARGOVAX ANNOUNCES COLLABORATION TO EVALUATE ONCOS-102 IN COMBINATION WITH KEYTRUDA[®] IN MESOTHELIOMA

BRIEF-Merck’s Keytruda Approved In China For Esophageal Squamous Cell Carcinoma

* MERCK’S KEYTRUDA (PEMBROLIZUMAB) APPROVED IN CHINA FOR SECOND-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE TUMORS EXPRESS PD-L1 (CPS ≥10)

BRIEF-Merck Announces V114 Met Safety, Immunogenicity Objectives In Initial Phase 3 Studies In Adults

* MERCK ANNOUNCES THAT V114, ITS INVESTIGATIONAL 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE, MET SAFETY AND IMMUNOGENICITY OBJECTIVES IN INITIAL PHASE 3 STUDIES IN ADULTS

BRIEF-Merck Completes Acquisition Of Themis

* MERCK - U.S. FTC HAS GRANTED EARLY TERMINATION OF WAITING PERIOD & CO RECEIVED MERGER CONTROL CLEARANCE FROM AUSTRIAN FEDERAL COMPETITION AUTHORITY Source text for Eikon: Further company coverage:

BRIEF-FDA Approves Second Biomarker-Based Indication For Merck's Keytruda

* FDA APPROVES SECOND BIOMARKER-BASED INDICATION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB), REGARDLESS OF TUMOR TYPE

BRIEF-Merck Prices $4.5 Billion Debt Offering

* MERCK - NOTES PRICED INCLUDE $1.0 BILLION OF 0.750% NOTES DUE 2026

BRIEF-Merck And Pfizer's Steglatrotm Meets Primary Endpoint

* MERCK AND PFIZER’S SGLT2 INHIBITOR STEGLATROTM (ERTUGLIFLOZIN) MEETS PRIMARY ENDPOINT IN VERTIS CV TRIAL FOR PATIENTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

BRIEF-Merck & Co Files For 4-Part, Notes Offering Size Not Disclosed

* MERCK & CO INC FILES FOR 4-PART, NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING Source: (https://bit.ly/2Y5zcDD) Further company coverage:

BRIEF-Merck & Co Says It Was Expanding Safer Childbirth Cities Initiative

* MERCK & CO INC - ANNOUNCED TODAY IT WAS EXPANDING ITS SAFER CHILDBIRTH CITIES INITIATIVE

BRIEF-FDA Approves Merck's Gardasil 9 For Prevention Of Certain HPV-Related Head And Neck Cancers

* FDA APPROVES MERCK’S GARDASIL 9 FOR THE PREVENTION OF CERTAIN HPV-RELATED HEAD AND NECK CANCERS

Japan's PeptiDream to work with Merck in developing COVID-19 therapies

Japanese drug-discovery company PeptiDream Inc said on Friday it would collaborate with Merck & Co in developing COVID-19 therapies.

IN BRIEF: Fed Circuit deals loss to Merck in birth control patent case

The U.S. Court of Appeals of the Federal Circuit on Tuesday dealt a setback to Merck & Co Inc in its effort to escape a patent infringement case relating to Nexplanon, an implantable contraceptive device that Merck has predicted will have $1 billion in annual sales.

Merck's bladder cancer late-stage study fails to meet main goals

Merck & Co said on Tuesday its blockbuster therapy Keytruda used along with chemotherapy failed to meet the main goals of a late-stage study testing the combination as a first-line treatment for bladder cancer.

Merck's bladder cancer late-stage study fails to meet main goals

Merck & Co said on Tuesday a late-stage study assessing its cancer drug Keytruda as a first-line treatment for bladder cancer failed to meet the main goals.

BRIEF-Merck Provides Update On Phase 3 Keynote-361 Trial Evaluating Keytruda

* MERCK PROVIDES UPDATE ON PHASE 3 KEYNOTE-361 TRIAL EVALUATING KEYTRUDA® (PEMBROLIZUMAB) AS MONOTHERAPY AND IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

BRIEF-FDA Approves Merck’s Recarbrio For Treatment Of Adults With Hospital-Acquired Pneumonia

* FDA APPROVES MERCK’S RECARBRIO™ (IMIPENEM, CILASTATIN, AND RELEBACTAM) FOR THE TREATMENT OF ADULTS WITH HOSPITAL-ACQUIRED AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) Source text for Eikon: Further company coverage:

BRIEF-Junshi Biosciences And Merck Announce Collaboration To Explore Promising New Combination Treatment For Head And Neck Cancer Patients In China

* JUNSHI BIOSCIENCES AND MERCK ANNOUNCE COLLABORATION TO EXPLORE PROMISING NEW COMBINATION TREATMENT FOR HEAD AND NECK CANCER PATIENTS IN CHINA Source text for Eikon: Further company coverage:

BRIEF-Lynparza Receives Positive Opinion From EU CHMP For Treatment Of Pancreatic Cancer

* LYNPARZA® (OLAPARIB) RECEIVES POSITIVE OPINION FROM EU CHMP FOR FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH GERMLINE BRCA-MUTATED METASTATIC PANCREATIC CANCER

BRIEF-AstraZeneca-Merck Lynparza Gets Recommendation For Approval By EMA

* ASTRAZENECA PLC - LYNPARZA EU CHMP OPINION IN PANCREATIC CANCER

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up